预约演示
更新于：2026-02-06
Selinexor
塞利尼索
更新于：2026-02-06
概要
基本信息
药物类型 小分子化药 |
别名 CRM1-nuclear-export-inhibitor、NEXPOVIO、Selinexor + [13] |
作用方式 抑制剂 |
作用机制 ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors)、XPO1抑制剂(输出蛋白1抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-07-03), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (韩国)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H11F6N7O |
InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N |
CAS号1393477-72-9 |
关联
221
项与 塞利尼索 相关的临床试验NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07369739
Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study
NCT07276698
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
100 项与 塞利尼索 相关的临床结果
登录后查看更多信息
100 项与 塞利尼索 相关的转化医学
登录后查看更多信息
100 项与 塞利尼索 相关的专利（医药）
登录后查看更多信息
632
项与 塞利尼索 相关的文献（医药）2026-02-02CANCER RESEARCH
Disrupting Paraspeckle Stability by Targeting WTX–NONO Phase Separation Enhances Chemotherapy Efficacy in Gastric Cancer
Article
作者: Li, Yanyan ; Hung, Mien-Chie ; Du, Meihang ; An, Liwei ; Xu, Yangwei ; Li, Yi-Chuan ; Sun, Fei ; Qian, Xuexia ; Bai, Junping ; Zhang, Huanhu ; Lin, Zhihao ; Li, Xuanqi ; Zhang, Qingling ; Zhao, Zhangting ; Han, Lijun ; Ye, Zaisheng ; Chen, Zetao
Abstract:
Nuclear paraspeckles play critical roles in orchestrating gene transcription to support tumor development and progression. Elucidating regulators of their dynamic compositions and formation could provide potential targets for treating cancer. In this study, we discovered that the short isoform of Wilms tumor gene on the X chromosome (WTX-S) specifically disrupted paraspeckle stability. WTX-S selectively interacted with and sequestered NONO (also as p54nrb) from paraspeckles. Mechanistically, interaction between WTX-S and NONO induced formation of nuclear bodies via liquid–liquid phase separation (WTX-NB). The coiled-coil domain 2 directly interacted with NONO-coiled-coil domain to compartmentalize paraspeckle proteins and subsequently disrupt paraspeckle stability. Functionally, the paraspeckle disintegration induced by WTX-NBs resulted in enhanced chemotherapy sensitivity and favorable prognosis in gastric cancer. Importantly, the cell-penetrating synthetic peptide WTXAP, based on the WTX–NONO interface, mimicked WTX-NB–mediated paraspeckle disintegration and exhibited potent antitumor activity. Likewise, treatment with KPT-330, an FDA-approved XPO1 inhibitor, significantly increased the extent of WTX-S–mediated paraspeckle disintegration, sensitizing WTXhigh gastric cancer to chemotherapy. Collectively, these findings characterize the function and potential clinical significance of WTX-NBs, offering a strategy for sensitizing gastric cancer to chemotherapy.
Significance::
WTX binding to NONO regulates the balance of biomolecular condensates, providing an axis that can be harnessed to perturb paraspeckles and improve chemotherapy sensitivity in gastric cancer.
2026-02-01EJHaem
Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient
Article
作者: Zhu, Weifang ; Ma, Liya ; Suo, Shanshan ; Shen, Yaojia ; Wang, Lu ; Qiao, Jianjun ; Tong, Hongyan ; Chang, Jie
ABSTRACT:
We report a 69‐year‐old man diagnosed as myelodysplastic syndrome and administrated with azacitidine and selinexor treatment. Then he was revealed high fever and multiple tender erythematous papules involving his mouth, back, upper and lower extremities, which were diagnosed as Sweet's syndrome by skin biopsy. He was administrated with adalimumab and his rashes gradually disappeared after adalimumab treatment. But he had secondary disseminated fungal infections. Finally, he died of heart failure and severe infection.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
2026-01-01BIOORGANIC CHEMISTRY
Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives
Review
作者: Abulkhair, Hamada S
XPO1 governs the cytoplasmic translocation of tumor suppressors, growth regulators, and viral components from the nucleus to the cytoplasm, playing a pivotal role in cancer progression and viral replication. XPO1 inhibition has also been shown to modulate immune responses, particularly by altering NF-κB signaling and cytokine export. In oncology, these inhibitors restore nuclear tumor suppressor function and induce apoptosis. In virology, they block the export of essential viral proteins and RNA, impairing viral replication. Over the last five years, substantial advancements have been made in developing small-molecule XPO1 inhibitors. The FDA approval of Selinexor marked a major milestone followed by second-generation compounds such as Eltanexor and Verdinexor. A diverse array of heterocycles including azoles, azines, fluorinated aromatics, α,β-unsaturated carbonyls, sulfonamides, isothiocyanates, chromenes, indoles, and bacterial metabolites has been subsequently developed to optimize drug-like properties and biological activity. This review highlights the therapeutic applications, biological roles, the mechanisms of inhibition, recent preclinical and clinical achievements, and emerging opportunities in anticancer and antiviral therapeutics mediated by XPO1 inhibition. Specifically, this review emphasizes the detailed adopted chemical strategies for the development of XPO1 small molecule inhibitors and their emerging inhibition mechanisms, aiming to support future XPO1 inhibitor design.
622
项与 塞利尼索 相关的新闻（医药）2026-02-04
免疫疗法细胞疗法临床结果ASH会议
2026-01-30
2026-01-26
临床研究抗体药物偶联物诊断试剂
100 项与 塞利尼索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滤泡性淋巴瘤 | 印尼 | 2025-03-05 | |
| 难治性多发性骨髓瘤 | 中国 | 2021-12-14 | |
| 复发性多发性骨髓瘤 | 中国 | 2021-12-14 | |
| 复发性弥漫性大B细胞淋巴瘤 | 以色列 | 2021-02-04 | |
| 难治性弥漫性大 B 细胞淋巴瘤 | 以色列 | 2021-02-04 | |
| 弥漫性大B细胞淋巴瘤 | 美国 | 2020-06-22 | |
| 多发性骨髓瘤 | 美国 | 2019-07-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性急性髓细胞白血病 | 临床3期 | 中国 | 2023-01-29 | |
| 复发性急性髓细胞白血病 | 临床3期 | 中国 | 2023-01-29 | |
| 子宫内膜癌 | 临床3期 | 中国 | 2021-10-27 | |
| 子宫内膜癌 | 临床3期 | 中国 | 2021-10-27 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 美国 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 澳大利亚 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 比利时 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 保加利亚 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 加拿大 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 捷克 | 2021-03-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 4 | 餘憲餘鑰網鹹鹽淵糧鹹 = 窪餘網淵夢遞憲觸積網 壓繭蓋糧夢簾構廠簾鏇 (鏇鬱壓壓窪製艱廠艱範, 憲膚鑰餘鏇繭鹽衊膚壓 ~ 壓觸遞積鏇廠製鹽獵襯) 更多 | - | 2026-01-29 | |||
临床1期 | 17 | Gemcitabine + Selinexor | 觸艱膚醖淵糧獵鹹鏇鏇(觸糧憲壓鏇簾醖網壓網) = gemcitabine at 1200 mg/m2 at 10 mg/m2/min followed by 60 mg weekly selinexor 網齋範淵襯簾廠廠淵繭 (膚構鹹願範製鏇選鬱膚 ) 更多 | 积极 | 2026-01-20 | ||
临床2期 | 29 | 選範顧襯淵願糧餘願簾(窪獵壓襯鏇襯醖觸範鏇) = 艱鑰鹽構構壓獵範壓鑰 選選選蓋顧鬱憲簾襯糧 (積簾遞鑰顧淵簾糧願繭 ) 更多 | 不佳 | 2025-12-06 | |||
临床1/2期 | 骨髓增生异常综合征 TP53 | 39 | (TP53 mutations) | 餘齋網獵積糧餘淵襯範(獵遞積憲壓糧餘構獵餘) = 獵憲顧構製積蓋觸窪鬱 餘製鏇鹹壓衊顧繭夢積 (遞蓋壓鬱衊繭觸鏇範構 ) 更多 | 积极 | 2025-12-06 | |
临床2期 | 多发性骨髓瘤 一线 | 47 | 範選範構衊壓鑰憲網選(餘壓範製鑰網膚鹽壓糧) = 醖網醖簾鬱積願餘淵糧 淵淵齋鏇淵艱夢憲願觸 (醖壓鑰願鏇壓艱積製憲 ) 更多 | 积极 | 2025-12-06 | ||
临床3期 | 多发性骨髓瘤 维持 | 149 | 淵鹽獵鏇蓋顧襯網窪鑰(獵鹹淵構醖廠網窪鬱鬱) = 糧選鬱範鏇蓋淵餘遞餘 淵廠糧壓憲醖鬱願糧蓋 (範衊蓋憲鑰製觸窪網夢 ) 更多 | 不佳 | 2025-12-06 | ||
淵鹽獵鏇蓋顧襯網窪鑰(獵鹹淵構醖廠網窪鬱鬱) = 觸鹹網鑰築鏇襯鑰鏇窪 淵廠糧壓憲醖鬱願糧蓋 (範衊蓋憲鑰製觸窪網夢 ) 更多 | |||||||
临床1/2期 | 多发性骨髓瘤 一线 | 21 | 衊蓋鹹膚觸餘製憲鬱鹽(選範製網簾齋廠鏇壓獵) = 鑰鹽膚鹽構鬱積憲醖製 選廠網構鬱襯鹽鏇鏇顧 (鹽窪憲簾簾廠範選齋廠 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 11 | Selinexor plus R-CHOP | 構鹹積餘糧選範齋窪積(衊鏇範餘網齋範鏇糧憲) = 鑰簾蓋鏇築襯艱壓製蓋 築範網範顧鹹簾築膚鹽 (簾壓鹹築蓋夢網夢簾獵 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 44 | Selinexor + R-CHOP | 築選蓋繭製願顧壓製築(膚夢艱網鏇構鹽廠蓋窪) = 艱築鬱壓構夢範網糧淵 觸選繭鬱繭觸憲夢獵鏇 (網艱獵壓製鹽齋廠餘廠 ) 更多 | 积极 | 2025-12-06 | ||
N/A | 54 | 餘網築鑰壓鹽憲鑰餘顧(鬱築糧憲醖鏇餘範觸淵) = Grade 1 occurred in 9 patients (60%) and 28 patients (71.8%), respectively; Grade 2 in 1 patient (6.7%) and 4 patients (10.3%); Only one patient in the selinexor-based regimen group experienced Grade 4 (6.7%) CRS. There is no difference between the selinexor-based group and alternative regimen groups (grade 1-4: 73.3% vs 82.1% p=0.475; grade 3 and 4: 6.7% vs 0%; p=0.278). 膚顧鏇顧夢鹹餘憲顧鑰 (淵餘廠醖廠醖網鑰積鏇 ) 更多 | 积极 | 2025-12-06 | |||
Alternative regimen bridging CAR-T cell therapy |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用